Novartis, CH0012005267

UBS keeps CHF 116 target for Novartis stock

Published on 10/16/2026 at 15:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis schedules third-quarter results for October 27, 2026. Novartis stock costs EUR 134.09 on October 16, 2026 at 3:19 p.m. CEST.

Target and reporting date

UBS analyst Matthew Weston maintained a Hold rating and set a CHF 116.00 target on October 15, 2026.
Novartis scheduled third-quarter results for October 27, 2026.
Novartis stock costs EUR 134.09 at Lang & Schwarz on October 16, 2026 at 3:19 p.m. CEST.
Novartis had a CHF 236.6 billion market capitalization and a 23.00 price-to-earnings ratio on October 16, 2026.

Isometrische Low-Poly-Illustration eines Pharmalabors mit Robotern und Inkubatoren — Novartis AG CH0012005267 – Isometrisches Low-Poly-Labor mit Robotern, Inkubatoren und vielen Wissenschaftlern, Illustration mit AI erstellt.

UBS analyst Matthew Weston maintained a Hold rating on Novartis AG and set a CHF 116.00 price target on October 15, 2026, according to Markets Insider. The target was 6.81 percent below Novartis stock's CHF 124.48 SIX price at 3:15 p.m. CEST on October 16, 2026. Novartis stock was trading at EUR 134.09 at Lang & Schwarz on October 16, 2026 at 3:19 p.m. CEST.

Results date adds a near-term marker

Novartis has scheduled its third-quarter results for October 27, 2026, giving investors a defined date for the next company update. The date appears on the company's investor calendar, which also lists a Remibrutinib in multiple sclerosis investor call for October 23, 2026, according to Novartis.

Stock stays below the yearly high

At CHF 124.48 on SIX, Novartis stood 6.18 percent below its 52-week high of CHF 132.68 and 28.27 percent above its 52-week low of CHF 97.05 on October 16, 2026. The Swiss listing had a market capitalization of CHF 236.6 billion, a price-to-earnings ratio of 23.00 and a dividend yield of 3.00 percent on the same date.

Valuation and calendar shape the view

The UBS target of CHF 116.00 provides a dated analyst reference below the SIX price, while the October 23 and October 27 calendar entries create two distinct near-term dates. The UBS report also cited quarterly revenue of CHF 14.16 billion and net profit of CHF 3.21 billion for the quarter ending June 30, 2026, compared with CHF 14.84 billion and CHF 4.04 billion a year earlier.

Trading perspective for Novartis stock

The immediate picture combines a CHF 116.00 analyst target with a scheduled results date and a share price still below its 52-week high. The different currencies matter: the Swiss valuation figures describe the SIX listing, while the German investor view uses the euro quotation.

Novartis stock was trading at EUR 134.09 at Lang & Schwarz on October 16, 2026 at 3:19 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Novartis stock.